Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inotrem S.A.
BioCentury | Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
BioCentury | Oct 25, 2022
Regulation
Oct. 25 Quick Takes: FDA approves J&J’s Tecvayli, first bispecific T cell engager for MM
Plus: Novartis prunes programs and updates from Ipsen, Biogen, Astellas-Taysha, Alto, AZ and more
BioCentury | Oct 19, 2022
Management Tracks
New chairs at SomaLogic, Anjarium
Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Oct 14, 2022
Finance
Oct. 14 Quick Takes: Sofinnova Partners, Mérieux back French ADC company Mablink
Plus Enliven finds path to NASDAQ via Imara deal and updates from Reata, Travere, Fujifilm, Inotrem, Obatala
BioCentury | Mar 25, 2022
Data Byte
The TREM1 pipeline gets one more therapy
Celsius throws its hat in the ring for a first-in-class IBD treatment
BioCentury | Jul 13, 2021
Product Development
July 12 Quick Takes: WHO gene editing recommendations go beyond germline to more immediate therapeutic applications; plus ProfoundBio, Incisive, EryDel, Inotrem and ReiThera
A pair of reports from the WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing covers not only the hot-button issue of human germline
BioCentury | Jun 10, 2021
Regulation
June 10 Quick Takes: Moderna submits COVID vaccine for adolescents in U.S., EU; plus Ocugen, NIH, BMS, Verona-Nuance and more
As FDA continues to grapple with questions of what safety data would support an emergency use authorization or licensure of COVID-19 vaccines in pediatric populations under 12 years old, Moderna Inc.
BioCentury | Mar 25, 2021
Management Tracks
Slaoui resigns from Vaxcyte, Centessa; plus moves at HHS, Fate, Inotrem, Immuneering, SwanBio and more
In the wake of sexual harassment allegations, former Operation Warp Speed leader Moncef Slaoui has resigned as chairman of Vaxcyte Inc. (NASDAQ:PCVX) and as CSO and adviser at Centessa Pharmaceuticals
BioCentury | Dec 31, 2020
Product Development
Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium
Sinopharm reveals top-line Phase III dataChina’s National Medical Products Administration (NMPA) granted conditional approval late Wednesday to an inactivated SARS-CoV-2 virus vaccine from
Items per page:
1 - 10 of 25